证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 编号：2023-004 投资者关系活动类 别 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 现场参观 其他 参与单位名称及人 员姓名 公司 2022 年度业绩说明会采用网络远程方式进行，面向全体投资者 时间 2023-5-11 地点 可孚医疗会议室 上市公司接待人员 姓名 董事长/总裁张敏；董事/副总裁/董事会秘书薛小桥；副总裁/财务总监陈望朋； 独立董事刘爱明；保荐代表人邹扬 投资者关系活动主 要内容介绍 1、请问下公司未来发展规划是什么？ 答：尊敬的投资者，您好！公司始终秉承"健康守护，关爱一生"的企业 宗旨，构建了覆盖各年龄层、全部消费群体的产品体系，致力于为用户提供终 身信赖的医疗健康产品和一站式解决方案，积极践行"健康中国战略"，为保 障人民群众健康安全、推动中国医疗器械产业的发展和提升中国医疗器械企业 在全球的地位而持续努力。 公司将研发创新作为推动持续发展的动力，基于积 累的良好研发基础，致力于新产品、新技术的创新突破以及现有产品技术升级， 开发满足消费者需求、具有更高科技 ...

更正公告 证券代码：301087 证券简称：可孚医疗 公告编号：2023-038 可孚医疗科技股份有限公司 关于《首次公开发行股票并在创业板上市之上市公告书》的 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"或"可孚医疗"）于 2021 年 10 月 22 日披露了《可孚医疗科技股份有限公司首次公开发行股票并在创业板 上市之上市公告书》（以下简称"《上市公告书》"），因工作人员疏忽，《上 市公告书》第二节之"二、股票上市相关信息"中，股东张志明先生持有的公司 首次公开发行前已发行股份可上市交易日期表述有误，现就有关内容进行更正， 具体情况如下： 一、张志明先生股份锁定的披露情况 公司在《首次公开发行股票并在创业板上市招股说明书》（以下简称"《招 股说明书》"）及《上市公告书》中披露的张志明先生股份锁定承诺情况如下： | 序号 | 文件名称 | 具体章节 | 承诺内容 | | --- | --- | --- | --- | | 1 | 《招股说 明书》 | 担任本公司董事、监事、高 级管理人员的股东关于股 | 担任本公 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2023-037 可孚医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）2022 年年度报告全文及 其摘要于 2023 年 4 月 26 日在巨潮资讯网（http://www.cninfo.com.cn）披露。 为便于广大投资者进一步了解公司 2022 年度经营情况，公司定于 2023 年 5 月 11 日（星期四）下午 15:00-17:00 举办 2022 年度网上业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆深圳证券交易所"互动易" 平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长、总裁张敏先生，董事、副总裁、 董事会秘书薛小桥先生，独立董事刘爱明先生，副总裁兼财务总监陈望朋先生， 保荐代表人邹扬先生。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 资者公开征集问 ...

可孚医疗科技股份有限公司2022年年度报告全文 可孚医疗科技股份有限公司 2022 年年度报告 2023-021 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥855,367,818.78, representing a 42.38% increase compared to ¥600,753,831.09 in the same period last year[5] - Net profit attributable to shareholders was ¥134,514,033.42, a significant increase of 167.93% from ¥50,204,732.44 year-on-year[5] - The basic earnings per share rose to ¥0.65, up 170.83% from ¥0.31 in the previous year[5] - Operating profit for Q1 2023 was ¥157,563,269.47, compared to ¥59,566,256.94 in Q1 2022, reflecting a growth of 164.6%[23] - Net profit for Q1 2023 amounted to ¥155,540,561.37, a substantial increase from ¥58,840,441.70 in the previous year[23] - The net profit for Q1 2023 was CNY 133,373,483.95, a significant increase of 153% compared to CNY 52,632,513.24 in the same period last year[25] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.65, up from CNY 0.24 in Q1 2022, representing a 171% increase[25] Cash Flow and Liquidity - Operating cash flow improved to ¥154,022,832.30, a turnaround from a negative cash flow of ¥317,768,933.80 in the same period last year, marking a 148.47% increase[5] - The net cash flow from operating activities was ¥154,022,832.30, a significant improvement from the previous period's negative cash flow of -¥317,768,933.80, representing a change of -148.47% due to reduced payments to suppliers and increased sales collections[14] - Cash flow from operating activities generated a net cash inflow of CNY 154,022,832.30, compared to a net outflow of CNY 317,768,933.80 in the previous year[28] - Cash and cash equivalents at the end of the period were ¥1,417,777,818.28, slightly down from ¥1,449,959,044.04 at the beginning of the year[22] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,320,497,604.99, down from CNY 1,730,252,830.26 at the end of Q1 2022[29] Expenses and Costs - Total operating costs for Q1 2023 were ¥676,950,984.19, up 26.3% from ¥536,028,236.07 in Q1 2022[23] - Research and development expenses increased by 39.82% to ¥29,501,924.78, reflecting higher personnel costs and material expenses[13] - The company reported a significant increase in research and development expenses, which rose to ¥29,501,924.78 from ¥21,100,488.96, marking an increase of 39.6%[23] - The company reported a 57.12% increase in sales expenses, totaling ¥195,901,260.69, due to higher service fees and marketing costs[13] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥6,360,300,564.21, a slight decrease of 0.79% from ¥6,410,837,630.17 at the end of the previous year[5] - Total assets decreased to ¥6,360,300,564.21 from ¥6,410,837,630.17, a decline of 0.8%[22] - Total liabilities decreased to ¥1,326,522,271.57 from ¥1,377,934,885.05, a reduction of 3.7%[22] - The company experienced a 253.00% increase in long-term borrowings, reaching ¥106,000,000.00, primarily due to new loans taken during the period[11] Shareholder Information and Repurchase Plans - As of the end of the reporting period, the total number of ordinary shareholders was 23,304, with no preferred shareholders[16] - The largest shareholder, Changsha Medical Investment Co., Ltd., holds 40.81% of the shares, amounting to 85,079,923 shares, with 23,010,000 shares pledged[16] - The company plans to repurchase shares using self-owned funds, with a total repurchase amount not less than ¥100 million and not exceeding ¥200 million, at a price not exceeding ¥60.00 per share[18] - As of March 31, 2023, the company had repurchased a total of 3,680,769 shares, representing 1.77% of the total share capital, with a total transaction amount of ¥136,317,242.94[19] - The highest repurchase price was ¥37.94 per share, while the lowest was ¥36.00 per share[19] - The company is focused on implementing an employee stock ownership plan or equity incentive through the repurchased shares[18] Strategic Focus - The report indicates a strategic focus on improving cash flow management and shareholder value through share repurchases and operational efficiency[14] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23] Other Financial Metrics - The company's weighted average return on equity improved to 2.69%, an increase of 1.68 percentage points from the previous year[5] - The impact of exchange rate fluctuations on cash and cash equivalents was -¥85,583.07, which is a 634.04% increase from -¥11,659.26 in the previous period, attributed to increased exchange rate volatility[14] - The company reported a total cash outflow from financing activities of CNY 413,806,436.72, compared to CNY 240,826,576.86 in the previous year[29] - The net cash flow from investing activities was negative CNY 115,099,925.82, an improvement from negative CNY 163,099,190.61 in the same period last year[28] - The company received CNY 324,848,762.14 in cash from borrowings during Q1 2023, compared to CNY 498,163,187.40 in the previous year[28] - The report for Q1 2023 was not audited[30]

编号：2021-006 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------|------------------------------------------------------------------------| | 投资者关系活动类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n☑其他 电话会议 | □分析师会议 \n □业绩说明会 \n □路演活动 \n | | 参与单位名称及人员 | | 富国基金孙笑悦、蒲世林；安信基金池陈森；乘安资管王镜程；东证资管周琰； | | 姓名 | | 中海基金梁静静；东方基金蔡尚军；东吴自营于彦秋；工银瑞信基金李乾宁； | | | | 广发基金王琪；大成基金邹建、杨挺、陈泉龙、戴军；光大永明资产王申璐； | | | | 国寿安保基金祁善斌；泓澄投资樊翔宇；弘毅远方基金 ...

Group 1: Company Overview and Development Plans - The company has been deeply engaged in the medical device industry for over ten years, with leading products such as hearing aids and infrared thermometers [1] - Key research projects include continuous glucose monitoring and advanced ECG monitoring, among others [1] - In 2020, the revenue from self-produced products accounted for 51%, with plans to increase this ratio through new production bases [1] Group 2: Acquisition and Market Position - The acquisition of the "Beibeijia" brand aims to leverage its strong market presence in posture correction products, which has been a leading brand for 20 years [2] - The brand will be enhanced through collaborations with universities and medical institutions to meet medical correction standards [2] - The company plans to optimize marketing strategies and reduce operational costs through its strong e-commerce capabilities [2] Group 3: Impact of COVID-19 - The pandemic increased health awareness and demand for health-related products, leading to a surge in sales of thermometers and masks [2] - In 2021, as the pandemic situation improved, non-pandemic product revenues rebounded, with total revenue reaching 1.698 billion yuan and net profit of 304 million yuan [2] Group 4: Hearing Loss and Service Model - Hearing loss is categorized into conductive, sensorineural, and mixed types, with recommendations for hearing aids for patients unable to restore normal hearing [2] - The company has established over 300 hearing aid fitting centers, employing a direct management model to ensure service quality and brand recognition [3][4]